120 related articles for article (PubMed ID: 683404)
1. Myoinositol--a uremic neurotoxin?
Blumberg A; Esslen E; Bürgi W
Nephron; 1978; 21(4):186-91. PubMed ID: 683404
[TBL] [Abstract][Full Text] [Related]
2. Experimental studies on pathogenesis and progression of uremic neuropathy in rats. II. Is plasma myoinositol a uremic neurotoxin?
Onishi S; Kawasaki T; Hamada K
Bull Osaka Med Sch; 1986 Oct; 32(2):66-72. PubMed ID: 3427262
[No Abstract] [Full Text] [Related]
3. Plasma-myoinositol concentrations in uraemic neuropathy.
Reznek RH; Salway JG; Thomas PK
Lancet; 1977 Mar; 1(8013):675-6. PubMed ID: 66475
[TBL] [Abstract][Full Text] [Related]
4. Plasma, red cell and cerebrospinal fluid concentrations of myoinositol in patients with severe chronic renal failure.
Servo C; Bardy A; Pasternack A; Pitkänen E
Ann Clin Res; 1976 Dec; 8(6):374-7. PubMed ID: 1008476
[TBL] [Abstract][Full Text] [Related]
5. The influence of glomerular filtration rate on uremic polyneuropathy.
Savazzi GM; Migone L; Cambi V
Clin Nephrol; 1980 Feb; 13(2):64-72. PubMed ID: 6244910
[No Abstract] [Full Text] [Related]
6. Raised plasma-myoinositol levels in uraemia and experimental neuropathy.
Clements RS; DeJesus PV; Winegrad AI
Lancet; 1973 May; 1(7813):1137-41. PubMed ID: 4123536
[No Abstract] [Full Text] [Related]
7. Role of platelet surface receptor abnormalities in the bleeding and thrombotic diathesis of uremic patients on hemodialysis and peritoneal dialysis.
Salvati F; Liani M
Int J Artif Organs; 2001 Mar; 24(3):131-5. PubMed ID: 11314805
[TBL] [Abstract][Full Text] [Related]
8. Variations in motor nerve conduction velocity in normal and uremic patients.
Kominami N; Tyler HR; Hampers CL; Merrill JP
Arch Intern Med; 1971 Aug; 128(2):235-239. PubMed ID: 4327548
[No Abstract] [Full Text] [Related]
9. [A comparison of the efficiency of eliminating middle-weight molecules and myoinositol from plasma during hemoperfusion and hemodialysis in cases of chronic uremia].
Trznadel K; Kidawa Z; Walasek L; Lutz W
Pol Tyg Lek; 1978 Feb; 33(7):257-9. PubMed ID: 758030
[No Abstract] [Full Text] [Related]
10. [Anti-inflammatory action of myoinositol in renal insufficiency].
Rysz J; Bartnicki P; Błaszczak R; Kujawski K; Ciałkowska-Rysz A; Olszewski R; Markuszewski L
Pol Merkur Lekarski; 2006 Feb; 20(116):180-3. PubMed ID: 16708635
[TBL] [Abstract][Full Text] [Related]
11. The "unphysiology" of dialysis: a major cause of dialysis side effects?
Kjellstrand CM; Evans RL; Petersen RJ; Shideman JR; von Hartitzsch B; Buselmeier TJ
Kidney Int Suppl; 1975 Jan; (2):30-4. PubMed ID: 1057690
[No Abstract] [Full Text] [Related]
12. Search for the uremic toxin. Decreased motor-nerve conduction velocity and elevated parathyroid hormone in uremia.
Avram MM; Feinfeld DA; Huatuco AH
N Engl J Med; 1978 May; 298(18):1000-3. PubMed ID: 205786
[TBL] [Abstract][Full Text] [Related]
13. Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes.
Greene DA; De Jesus PV; Winegrad AI
J Clin Invest; 1975 Jun; 55(6):1326-36. PubMed ID: 124320
[TBL] [Abstract][Full Text] [Related]
14. [Velocity of maximal motor nerve conduction in polyneuropathies of uremic patients subjected to various types of hemodialysis for varying periods of time: values and limitations].
Savazzi GM; Arisi L; Bignardi L; Rossi E; Cambi V; Allegri L
Riv Neurol; 1976; 46(1):25-35. PubMed ID: 1013604
[No Abstract] [Full Text] [Related]
15. Accumulation of myoinositol in plasma and red cells of diabetic patients.
Servo C
Acta Med Scand; 1977 Jan; 201(1-2):59-62. PubMed ID: 835372
[TBL] [Abstract][Full Text] [Related]
16. Uremic neuropathy: evidence of middle molecule toxicity.
Milutinovic J; Babb AL; Eschbach JW; Follette WC; Graefe U; Strand MJ; Scribner BH
Artif Organs; 1978 Feb; 2(1):45-51. PubMed ID: 687020
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid sorbitol and myoinositol in diabetic polyneuropathy.
Servo C; Bergström L; Fogelholm R
Acta Med Scand; 1977; 202(4):301-4. PubMed ID: 920249
[TBL] [Abstract][Full Text] [Related]
18. Variation in polyol levels in cerebrospinal fluid and serum in diabetic patients.
Servo C; Pitkänen E
Diabetologia; 1975 Dec; 11(6):575-80. PubMed ID: 1205026
[TBL] [Abstract][Full Text] [Related]
19. [Uremic neuropathies. Comparative study of the velocity of motor and nerve conduction during predialysis, hemodialysis and postransplantation periods].
Fernández González F
Arch Neurobiol (Madr); 1976; 39(1):15-36. PubMed ID: 776116
[No Abstract] [Full Text] [Related]
20. [Uremic neuropathy--I. Is uremic neuropathy related to patient age, duration of nephropathy and dialysis treatment?].
Jedras M; Zakrzewska-Pniewska B; Wardyn K; Switalski M
Pol Arch Med Wewn; 1998 Jun; 99(6):452-61. PubMed ID: 10085699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
